ES2165109T3 - Vacuna mejorada para la inmunizacion contra infecciones por el virus de la tbe y procedimiento para su preparacion. - Google Patents

Vacuna mejorada para la inmunizacion contra infecciones por el virus de la tbe y procedimiento para su preparacion.

Info

Publication number
ES2165109T3
ES2165109T3 ES98107383T ES98107383T ES2165109T3 ES 2165109 T3 ES2165109 T3 ES 2165109T3 ES 98107383 T ES98107383 T ES 98107383T ES 98107383 T ES98107383 T ES 98107383T ES 2165109 T3 ES2165109 T3 ES 2165109T3
Authority
ES
Spain
Prior art keywords
tbe
protein
virus
immunization against
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98107383T
Other languages
English (en)
Inventor
Xaver-Franz Prof Dr Heinz
Steven Dr Allison
Christian Doz Dr Mandl
Christian Prof Dr Kunz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0135294A external-priority patent/AT402897B/de
Priority claimed from AT0087195A external-priority patent/AT405607B/de
Application filed by Baxter AG filed Critical Baxter AG
Application granted granted Critical
Publication of ES2165109T3 publication Critical patent/ES2165109T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION DESCRIBE UNA VACUNA PARA LA INMUNIZACION CONTRA LAS INFECCIONES VIRICAS CON TBE QUE INCLUYE PARTICULAS SUBVIRALES NO INFECCIOSAS, QUE INCLUYEN LA PROTEINA E Y EVENTUALMENTE LA PROTEINA PRM/M, SU VACUNA QUE INCLUYE UN ACIDO NUCLEICO, PARA LA PROTEINA E Y LA PROTEINA PRM/M, QUE DERIVA DEL VIRUS TBE, DONDE LA PROTEINA E ESTA O SE CODIFICA ESENCIALMENTE DE FORMA COMPLETA EN FORMA NATIVA.
ES98107383T 1994-07-08 1995-07-06 Vacuna mejorada para la inmunizacion contra infecciones por el virus de la tbe y procedimiento para su preparacion. Expired - Lifetime ES2165109T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0135294A AT402897B (de) 1994-07-08 1994-07-08 Verbesserte vakzine zur immunisierung gegen tbe-virusinfektionen sowie ein verfahren zu dessen herstellung
AT0087195A AT405607B (de) 1995-05-23 1995-05-23 Verbesserte vakzine zur immunisierung gegen tbe-virusinfektionen sowie ein verfahren zu dessen herstellung

Publications (1)

Publication Number Publication Date
ES2165109T3 true ES2165109T3 (es) 2002-03-01

Family

ID=25594155

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95890132T Expired - Lifetime ES2155510T3 (es) 1994-07-08 1995-07-06 Vacuna mejorada para la inmunizacion contra infecciones por el virus tbe y procedimiento para su preparacion.
ES98107383T Expired - Lifetime ES2165109T3 (es) 1994-07-08 1995-07-06 Vacuna mejorada para la inmunizacion contra infecciones por el virus de la tbe y procedimiento para su preparacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES95890132T Expired - Lifetime ES2155510T3 (es) 1994-07-08 1995-07-06 Vacuna mejorada para la inmunizacion contra infecciones por el virus tbe y procedimiento para su preparacion.

Country Status (9)

Country Link
EP (2) EP0691404B1 (es)
AT (2) ATE206459T1 (es)
CZ (1) CZ282927B6 (es)
DE (2) DE59508988D1 (es)
DK (2) DK0869184T3 (es)
ES (2) ES2155510T3 (es)
FI (2) FI117974B (es)
HU (2) HU219503B (es)
RU (1) RU2150294C1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69833388D1 (de) * 1997-11-20 2006-04-13 Us Army Medical Res Materiel C Dna impfstoffe gegen zecken-flavivieren
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
NZ535690A (en) 2002-02-26 2009-04-30 Maxygen Inc Novel flavivirus antigens
AU2005318171B2 (en) 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
CN103351435B (zh) 2006-06-06 2015-08-19 克鲁塞尔荷兰公司 具有杀灭葡萄球菌活性的人结合分子及其应用
CA2960659C (en) 2007-11-09 2021-07-13 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853693D1 (de) * 1987-03-20 1995-06-08 Immuno Ag DNA- und RNA-Moleküle des westlichen Subtyps des FSME-Virus, Polypeptide, die von diesen Molekülen codiert werden, und deren Verwendung.
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
WO1992003161A1 (en) 1990-08-27 1992-03-05 The United States Of America, Represented By The Secretary, United States Department Of Commerce Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection
JP3881689B2 (ja) 1992-03-11 2007-02-14 パウダージェクト ヴァクシンズ，インコーポレイテッド 免疫不全ウイルス用の遺伝子ワクチン

Also Published As

Publication number Publication date
EP0869184B1 (de) 2001-10-04
EP0869184A3 (de) 1999-05-12
ES2155510T3 (es) 2001-05-16
FI118222B (fi) 2007-08-31
ATE206459T1 (de) 2001-10-15
ATE198909T1 (de) 2001-02-15
CZ282927B6 (cs) 1997-11-12
FI953371A (fi) 1996-01-09
DE59509667D1 (de) 2001-11-08
DE59508988D1 (de) 2001-03-01
DK0691404T3 (da) 2001-03-19
HU9501832D0 (en) 1995-08-28
EP0691404B1 (de) 2001-01-24
FI117974B (fi) 2007-05-15
EP0691404A2 (de) 1996-01-10
FI953371A0 (fi) 1995-07-07
RU2150294C1 (ru) 2000-06-10
EP0691404A3 (de) 1997-11-12
CZ176995A3 (en) 1996-01-17
HU219503B (hu) 2001-04-28
DK0869184T3 (da) 2001-12-17
HU9903233D0 (en) 1999-11-29
HU224199B1 (hu) 2005-06-28
HUT72395A (en) 1996-04-29
FI20070041A (fi) 2007-01-17
EP0869184A2 (de) 1998-10-07

Similar Documents

Publication Publication Date Title
FR2814958B1 (fr) Composition vaccinale
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
ATE426412T1 (de) Adjuvante influenza-vakzine
ATE542829T1 (de) Impfstoff
AR030829A1 (es) Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
BR9605153B1 (pt) vacina de combinação, e, kit de vacinação.
DE50015170D1 (de) Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
AR023535A1 (es) Nuevas composiciones.
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
MX9207113A (es) Fragmento de adn, peptido que comprende una proteina superficial ha de un virus de gripe a y vacuna que comprende tal peptido.
NO20023829D0 (no) Proteosom influensavaksine
ATE144143T1 (de) Künstlicher impfstoff gegen aids-virus
BRPI0113155C1 (pt) métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
ES2070266T3 (es) Vacuna contra la infeccion por escherichia coli.
ES2165109T3 (es) Vacuna mejorada para la inmunizacion contra infecciones por el virus de la tbe y procedimiento para su preparacion.
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
BR0017052B1 (pt) Método para a projeção de um constructo poliepitópico e constructo poliepitópico preparado pelo referido método
CL2021002727A1 (es) Vacuna con subunidades del vfpc
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
ES2085163T3 (es) Vacunas contra los parasitos metazoos.
AR027443A1 (es) MUTANTES DE EHV gM-NEGATIVOS
DE60113299D1 (de) Neue vakzinformulierung aus dna-vakzine-inaktiviertem virus
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 869184

Country of ref document: ES